BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Barakat AAE, Nasr FM, Metwaly AA, Morsy S, Eldamarawy M. Atherosclerosis in chronic hepatitis C virus patients with and without liver cirrhosis. Egypt Heart J. 2017;69:139-147. [PMID: 29622968 DOI: 10.1016/j.ehj.2016.10.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Mohamed MA, Bayoumy EM, Swailam MM, Allam AS. Assessment of carotid atherosclerosis in Egyptian chronic hepatitis C patients after treatment by direct-acting antiviral drugs. Egypt Liver Journal 2022;12:54. [DOI: 10.1186/s43066-022-00218-8] [Reference Citation Analysis]
2 Gîrleanu I, Trifan A, Huiban L, Muzîca C, Petrea OC, Sîngeap AM, Cojocariu C, Chiriac S, Cuciureanu T, Costache II, Stanciu C. Ischemic Heart Disease and Liver Cirrhosis: Adding Insult to Injury. Life (Basel) 2022;12:1036. [PMID: 35888123 DOI: 10.3390/life12071036] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Dunaeva NV, Pervakova MY, Mazing AS, Lapin SV. Incidence and risk factors of extrahepatic manifestations in patients with chronic HCV and HCV/HIV infection. VIČ-infekc immunosupr 2022;13:53-63. [DOI: 10.22328/2077-9828-2021-13-4-53-63] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Medhioub M, Bouzaidi K, Bachali A, Khsiba A, Hamzaoui L, Azouz MM. The risk of subclinical carotid atherosclerosis in patients with chronic hepatitis C. Tunis Med 2021;99:449-55. [PMID: 35244930] [Reference Citation Analysis]
5 Ramadan FAF, Ahmed NAF, Aref SE, El Husseini MAG. Malnutrition inflammation index in chronic haemodialysis patients with or without hepatitis C virus infection. Egypt Liver Journal 2020;10:20. [DOI: 10.1186/s43066-020-00026-y] [Reference Citation Analysis]
6 Singh S, Bansal A, Kumar P. CRP Levels in Viral Hepatitis: A Meta-Analysis Study. Int J Infect 2020;8. [DOI: 10.5812/iji.108958] [Reference Citation Analysis]
7 Hanafy AS, Basha MAK, Wadea FM. Novel markers of endothelial dysfunction in hepatitis C virus-related cirrhosis: More than a mere prediction of esophageal varices. World J Hepatol 2020; 12(10): 850-862 [PMID: 33200022 DOI: 10.4254/wjh.v12.i10.850] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Sliem HA, Salem AS, Hussien WM, El Sayed HRA. Arterial wall structural changes in noncirrhotic chronic hepatitis C patients. Eur J Gastroenterol Hepatol 2019;31:1432-8. [PMID: 31569123 DOI: 10.1097/MEG.0000000000001429] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Hany NM, Hammouda AMA, Nabih ES, Mohamed SM. The potential regulatory role of miR16 to the interplay between interferon and transforming growth factor beta pathways through IRF3 and SMAD7 in hepatitis C virus infected patients. J Cell Biochem 2019;120:12694-701. [PMID: 30861602 DOI: 10.1002/jcb.28537] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]